StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)

他汀类药物可减少静脉血栓栓塞患者的静脉事件（SAVER 试验）

• 批准号: 401772
• 负责人: Delluc Aurelien
• 金额: $ 252.09万
• 依托单位: Ottawa Hospital Research Institute
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2024-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=401772&lang=en
• 关键词: Adjuvent; Arterial Vascular Events; Deep Vein Thrombosis; Post-Thrombotic Syndrome; Pulmonary Embolism; Randomized Controlled Trial; Rosuvastatin; Secondary Prevention; Statin; Venous Thromboembolism

Rosuvastatin belongs to a family of drugs called statins. They are prescribed for patients with elevated cholesterol levels and have been found to decrease the incidence of arterial events such as heart attack and stroke. It is possible that statins may a

瑞舒伐他汀属于他汀类药物家族。它们被用于胆固醇水平升高的患者，并被发现可以降低心脏病发作和中风等动脉事件的发生率。他汀类药物有可能